Skip to main content

Table 1 Postdiagnosis characteristics of the population by change in recommended levels of leisure-time physical activity pre- and postdiagnosis

From: Pre- to postdiagnosis leisure-time physical activity and prognosis in postmenopausal breast cancer survivors

 

Total

Pre- and postdiagnosis leisure-time physical activity

Insufficiently activea

Increasingly active

Decreasingly active

Sufficiently active

n (%)

2042 (100.0)

1037 (50.8)

348 (17.0)

285 (14.0)

372 (18.2)

Age at diagnosis, years, median (IQR)b

62.9 (58.6–66.4)

63.4 (59.1–67.1)

61.9 (58.0–65.3)

64.1 (59.5–67.1)

61.1 (57.3–64.4)

Physical activity prediagnosis, median (IQR)

 Walking (hours/week)b

6.0 (3.2–9.0)

6.0 (3.0–9.0)

6.0 (3.5–9.0)

7.0 (3.5–10.5)

6.0 (3.3–9.0)

 Cycling (hours/week)b

1.2 (0.0–3.5)

1.0 (0.0–3.5)

1.4 (0.0–4.0)

1.8 (0.0–4.0)

2.0 (0.0–4.0)

 Total (MET-h/week)b

43.1 (26.5–65.6)

35.0 (20.0–56.0)

38.7 (24.2–57.1)

59.2 (41.1–85.6)

59.5 (41.7–78.7)

Physical activity postdiagnosis, median (IQR)

 Walking (hours/week)b

6.0 (3.0–10.0)

6.0 (3.0–8.0)

6.0 (4.0–10.0)

6.0 (3.0–10.0)

7.0 (4.0–10.0)

 Cycling (hours/week)b

1.0 (0.0–3.0)

0.0 (0.0–2.3)

2.0 (0.0–4.0)

1.0 (0.0–3.0)

2.0 (0.0–3.5)

 Total (MET-h/week)b

40.0 (23.4–66.0)

29.6 (16.0–48.0)

56.6 (37.3–80.1)

33.1 (17.2–56.0)

62.2 (40.3–95.6)

BMI, median (IQR)b

25.3 (22.9–28.4)

25.8 (23.3–29.4)

25.0 (22.8–28.3)

24.8 (22.9–27.7)

24.4 (22.5–27.1)

Smoking status, n (%)

 Never

1108 (54.3)

580 (55.9)

179 (51.4)

157 (55.1)

192 (51.6)

 Former

748 (36.6)

341 (32.9)

141 (40.5)

105 (36.8)

161 (43.3)

 Current

186 (9.1)

116 (11.2)

28 (8.0)

23 (8.1)

19 (5.1)

Alcohol, g/day, median (IQR)b

0.7 (0.0–5.7)

0.6 (0.0–5.4)

0.7 (0.0–5.7)

2.0 (0.0–7.1)

1.4 (0.0–8.3)

Education, n (%)b

 Less than high/middle school

1141 (55.9)

659 (63.5)

182 (52.3)

151 (53.0)

149 (40.1)

 High/middle school

583 (28.6)

268 (25.8)

108 (31.0)

79 (27.7)

128 (34.4)

 College or university

318 (15.6)

110 (10.6)

58 (16.7)

55 (19.3)

95 (25.5)

Menopausal hormone use, n (%)

1000 (49.0)

483 (46.6)

171 (49.1)

150 (52.6)

196 (52.7)

Tumour size, cm, n (%)

 < 2

1159 (56.8)

566 (54.6)

199 (57.2)

168 (58.9)

226 (60.8)

 2–5

622 (30.5)

336 (32.4)

101 (29.0)

86 (30.2)

99 (26.6)

 > 5 and growth into chest wall/skin

73 (3.6)

46 (4.4)

11 (3.2)

8 (2.8)

8 (2.2)

 Neoadjuvant chemotherapyc

61 (3.0)

32 (3.1)

11 (3.2)

6 (2.1)

12 (3.2)

 In situ3

124 (6.1)

54 (5.2)

26 (7.5)

17 (6.0)

27 (7.3)

Number of positive lymph nodes, n (%)

 0

1322 (64.7)

690 (66.5)

209 (60.1)

170 (59.6)

253 (68.0)

 1–3

400 (19.6)

183 (17.6)

72 (20.7)

79 (27.7)

66 (17.7)

 > 3

135 (6.6)

78 (7.5)

30 (8.6)

13 (4.6)

14 (3.8)

Tumour grade, n (%)

 Low/moderate

1422 (69.6)

720 (69.4)

240 (69.0)

197 (69.1)

265 (71.2)

 High

426 (20.9)

223 (21.5)

71 (20.4)

64 (22.5)

68 (18.3)

Hormone receptor status, n (%)

 ER+/PR+

1238 (60.6)

628 (60.6)

208 (59.8)

175 (61.4)

227 (61.0)

 ER+/PR−, ER−/PR+

344 (16.8)

174 (16.8)

55 (15.8)

51 (17.9)

64 (17.2)

 ER−/PR−

275 (13.5)

149 (14.4)

48 (13.8)

36 (12.6)

42 (11.3)

HER2 status, n (%)

 HER2+

312 (15.3)

159 (15.3)

63 (18.1)

46 (16.1)

44 (11.8)

 HER2−

1413 (69.2)

715 (68.9)

228 (65.5)

197 (69.1)

273 (73.4)

 Missing, n (%)

132 (6.5)

77 (7.4)

20 (5.7)

19 (6.7)

16 (4.3)

Type of surgery, n (%)

 Mastectomy

55 (2.7)

24 (2.3)

11 (3.2)

9 (3.2)

11 (3.0)

 Mastectomy + axilla

478 (23.4)

266 (25.7)

85 (24.4)

57 (20.0)

70 (18.8)

 Breast-conserving therapy

181 (8.9)

86 (8.3)

31 (8.9)

25 (8.8)

39 (10.5)

 Breast-conserving therapy + axilla

1326 (64.9)

660 (63.6)

221 (63.5)

193 (67.7)

252 (67.7)

Mode of tumour detection, n (%)b

 Self-detected by palpation/secretion/pain

1007 (49.3)

550 (53.0)

151 (43.4)

136 (47.7)

170 (45.7)

 Routine examination, mammography, ultrasound

1031 (50.5)

485 (46.8)

195 (56.0)

149 (52.3)

202 (54.3)

Chemotherapy, n (%)

917 (44.9)

481 (46.4)

163 (46.8)

127 (44.6)

146 (39.2)

Radiation therapy, n (%)

1627 (79.7)

828 (79.8)

274 (78.7)

230 (80.7)

295 (79.3)

Hormone therapy, n (%)

1651 (80.9)

842 (81.2)

276 (79.3)

228 (80.0)

305 (82.0)

Diabetes, n (%)b

239 (11.7)

162 (15.6)

21 (6.0)

32 (11.2)

24 (6.5)

Cardiovascular disease, n (%)b

1349 (66.1)

737 (71.1)

227 (65.2)

180 (63.2)

205 (55.1)

Osteoporosis, n (%)

452 (22.1)

241 (23.2)

74 (21.3)

69 (24.2)

68 (18.3)

  1. aInsufficiently active is defined as having between 0 and 7.5 MET-h/week of leisure-time physical activity; sufficiently active is defined as having ≥ 7.5 MET-h/week of leisure-time physical activity
  2. bStatistically significant differences in patient characteristics between physical activity groups tested by ANOVA (p < 0.05 for statistical significance)
  3. cAlso for number of positive lymph nodes, tumour grade, ER/PR status, and HER2 status